Construction of an immune-related lncRNA pairs model to predict prognosis and immune landscape of lung adenocarcinoma patients

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1).
   Web of Science ®Google Scholar
• Yao RW, Wang Y, Chen LL. Cellular functions of long noncoding RNAs. Nat Cell Biol. 2019;21(5):542–551.
   PubMed Web of Science ®Google Scholar
• Chiu H-S, Somvanshi S, Patel E, et al. Pan-cancer analysis of lncRNA regulation supports their targeting of cancer genes in each tumor context. Cell Rep. 2018;23(1).
   Web of Science ®Google Scholar
• Atianand MK, Caffrey DR, Fitzgerald KA. Immunobiology of long noncoding RNAs. Annu Rev Immunol. 2017;35:177–198.
   PubMed Web of Science ®Google Scholar
• Jiang R, Tang J, Chen Y, et al. The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nat Commun. 2017;8:15129.
   PubMed Web of Science ®Google Scholar
• Chen C, He W, Huang J, et al. LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment. Nat Commun. 2018;9(1):3826.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Gou X, Wei Z, et al. Bioinformatics profiling integrating a three immune-related long non-coding RNA signature as a prognostic model for clear cell renal cell carcinoma. Cancer Cell Int. 2020;20:166.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang C, Zhang C, et al. Construction of immune-related and prognostic lncRNA clusters and identification of their immune and genomic alterations characteristics in lung adenocarcinoma samples. Aging (Albany NY). 2020;12(10):9868–9881.
   PubMedGoogle Scholar
• Xu J-Z, Gong C, Xie Z-F, et al. Development of an oncogenic driver alteration associated immune-related prognostic model for stage I-II lung adenocarcinoma. Front Oncol. 2020;10:593022.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Hu Z-Y, Huang W-Y, Zhang L, et al. Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis. Ann Transl Med. 2020;8(18):1172.
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo B-Y, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193–202.
   PubMed Web of Science ®Google Scholar
• Hong Y, Ding Z-Y. PD-1 Inhibitors in the Advanced Esophageal Cancer. Front Pharmacol. 2019;10:1418.
   PubMed Web of Science ®Google Scholar
• Lv Y, Lin S-Y, Hu FF, et al. Landscape of cancer diagnostic biomarkers from specifically expressed genes. Brief Bioinform. 2020;21(6):2175–2184.
   PubMed Web of Science ®Google Scholar
• Liu Z, Sun D, Zhu Q, et al. The screening of immune-related biomarkers for prognosis of lung adenocarcinoma. Bioengineered. 2021;12(1):1273–1285.
   PubMed Web of Science ®Google Scholar
• Jia Y, Duan Y, Liu T, et al. LncRNA TTN-AS1 promotes migration, invasion, and epithelial mesenchymal transition of lung adenocarcinoma via sponging miR-142-5p to regulate CDK5. Cell Death Dis. 2019;10(8):573.
   PubMed Web of Science ®Google Scholar
• Peng F, Wang R, Zhang Y, et al. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer. 2017;16(1):98.
   PubMedGoogle Scholar
• Hu W, Wang Y, Fang Z, et al. Integrated characterization of lncRNA-immune interactions in prostate cancer. Front Cell Dev Biol. 2021;9:641891.
   PubMed Web of Science ®Google Scholar
• Ko EC, Raben D, Formenti SC. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer. Clin Cancer Res. 2018;24(23):5792–5806.
   PubMed Web of Science ®Google Scholar
• Li Y, Jiang T, Zhou W, et al. Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers. Nat Commun. 2020;11(1):1000.
   PubMed Web of Science ®Google Scholar
• Galon J, Bindea G, Mlecnik B, et al. [Intratumoral immune microenvironment and survival: the immunoscore]. Med Sci (Paris). 2014;30(4):439–444.
   PubMed Web of Science ®Google Scholar
• Kirilovsky A, Marliot F, El Sissy C, et al. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol. 2016;28(8):373–382.
   PubMed Web of Science ®Google Scholar
• Taube JM, Galon J, Sholl LM, et al. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol. 2018;31(2):214–234.
   PubMed Web of Science ®Google Scholar
• Hong W, Liang L, Gu Y, et al. Immune-related lncRNA to construct novel signature and predict the immune landscape of human hepatocellular carcinoma. Mol Ther Nucleic Acids. 2020;22:937–947.
   PubMedGoogle Scholar
• Li X, Sun L, Wang X, et al. A five immune-related lncRNA signature as a prognostic target for glioblastoma. Front Mol Biosci. 2021;8:632837.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li L, Zhan Y, et al. Identification of immune-related lncRNA signature to predict prognosis and immunotherapeutic efficiency in bladder cancer. Front Oncol. 2020;10:542140.
   PubMed Web of Science ®Google Scholar
• Sveen A, Ågesen TH, Nesbakken A, et al. ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin Cancer Res. 2012;18(21):6001–6010.
   PubMed Web of Science ®Google Scholar
• Brambilla E, Le Teuff G, Marguet S, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. J Clin Oncol. 2016;34(11):1223–1230.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen J, Cheng T, et al. Identification of the key genes and characterizations of tumor immune microenvironment in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). J Cancer. 2020;11(17):4965–4979.
   PubMed Web of Science ®Google Scholar
• Dai G-P, Wang L-P, Wen Y-Q, et al. Identification of key genes for predicting colorectal cancer prognosis by integrated bioinformatics analysis. Oncol Lett. 2020;19(1):388–398.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhang Y, Li Y, et al. Time-programmed delivery of sorafenib and anti-CD47 antibody via a double-layer-gel matrix for postsurgical treatment of breast cancer. Nanomicro Lett. 2021;13(1):141.
   PubMed Web of Science ®Google Scholar